Navigation Links
Clinilabs Launches Research Volunteer Authentication Initiative Choosing Verified Clinical Trials to Stop Dual Enrollment in Clinical Trials
Date:4/2/2013

New York, NY (PRWEB) April 02, 2013

Clinilabs, an early phase and specialty CRO that provides clinical drug development services to industry, today announced that it has launched a subject authentication initiative at its Phase 1 sites in New York and New Jersey. This initiative includes the authentication of subject identity and medical history, background checks, and tracking of prior study participation in order to eliminate ineligible subjects from clinical trials. The Company has selected Verified Clinical Trials (VCT) to assist with this initiative, implementing the VCT clinical trials database registry system. VCT’s registry is designed to stop the professional research subjec t from enrolling in multiple clinical trials simultaneously – a situation known as dual enrollment. This collaboration between Clinilabs and VCT is a reflection of both companies’ commitment to volunteer safety and data quality.

Failure to document the identity of study volunteers, inaccuracies in subjects’ medical histories, and multiple concurrent enrollments have become a serious problem in the clinical research world. Study volunteers interested in free care or compensation may present inaccurate information in order to gain entry to clinical trials, and some may jump from one study to another without waiting for enough time to lapse between treatments. This type of research volunteer places everyone at risk including the drug manufacturer, the research site, and most importantly, themselves, potentially jeopardizing their health. Furthermore, this may compromise data quality.

Clinilabs and Verified Clinical Trials are determined to meet the challenge of subject enrollment in a proactive way, ensuring that only eligible subjects are enrolled in clinical trials. Dr. Gary Zammit, President and CEO states, "Most of us in the industry recognize the existence and the significant ramifications of improper enrollment in clinical trials, but we have never before been able to quantify it, detect it, or stop it. Clinilabs has taken the lead among CROs to provide its clients with a thoughtfully-conceived approach to subject authentication – ensuring the accuracy and integrity of volunteer data."

Dr. Mitchell Efros, CEO of Verified Clinical Trials states, "Clinilabs has joined an impressive cohort of companies on a local and national level to improve the quality of their trials. The recognition of dual enrollment in clinical research and use of the VCT system has literally exploded as of late". Dr. Efros adds, "We are very excited to have a company like Clinilabs join our expansive network that includes and focuses on both early and late phase trials. Clinilabs has joined the largest clinical research database network across North America and only strengthens this cooperative registry."

About Clinilabs Inc.

Clinilabs is a full-service contract research organization (CRO) that specializes in early-phase studies, from first-in-human to proof-of-concept, with normal healthy volunteers and patient populations. The company owns and operates two Phase I units in the US, and maintains a network of highly qualified investigator sites for multicenter Phase II studies Worldwide. Specialty projects, including pharmacodynamic, biomarker, cardiac safety, sleep/wakefulness, metabolic, and Japanese bridging are among our strengths. Clinilabs is recognized globally as a leading specialty CRO, offering an alternative to large CRO for specialty projects. For more information, please visit http://www.clinilabs.com.

About Verified Clinical Trials

Verified Clinical Trials is a forward thinking company developed by experts active in the clinical research community to proactively improve research subject safety and data quality in clinical research trials. Verified Clinical Trials halts dual enrollment in clinical trials and defines itself as the world's leader in the field of database registries in clinical trial research. Verified Clinical Trials is the only clinical research database registry designed specifically to enhance the quality of both early and late phase trials and has the scalability to reach all sites nationally as well as on a global level. Verified Clinical Trials offers numerous other value added services to the clinical research site, CRO, and Pharmaceutical Sponsor, that prove invaluable with regards to financial and legal issues and liabilities. For more information, visit http://www.verifiedclinicaltrials.com.

Clinilabs Contact:
Hannah D’Aoust
Phone: (646) 215-6480
hdaoust(at)clinilabs(dot)com

Verified Clinical Trials Contact:
Kerri Weingard ANP
Chief Operating Officer
Phone: (516) 998-7499
kweingard(at)verifiedclinicaltrials(dot)com

Read the full story at http://www.prweb.com/releases/ClinilabsVerifiedClinical/StopDualEnrollment/prweb10587136.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
2. Neighborhood Smiles Launches a Groundbreaking Cavity Prevention Program for Their Patients
3. Dr. Timothy Rauch of Albuquerque, New Mexico Launches a Groundbreaking Cavity Prevention Program
4. CellHealth Institute Launches with Support from Influential Investors
5. Dr. Richard Charmoy Launches Groundbreaking Cavity Prevention Program that Can Lower Tooth Decay Rates by 74%
6. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
7. BioHealth Innovation, Inc. Launches Program to Help Life Science Companies Navigate Federal Funding Application Process
8. Rockingham County Economic Development Launches New Website
9. Neogen launches rapid tests for ractopamine
10. Elsevier Launches PracticeUpdate, a Free Information Portal for Physicians
11. Guidepoint Global Launches Two Major Enhancements to its Client Research Portal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology:
(Date:10/4/2017)... Solutions, a global clinical research organization (CRO), announces the launch of ... 4, 2017. Shadow is designed to assist medical writers and biometrics ... the European Medicines Agency (EMA) in meeting the requirements for de-identifying ... ... ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 /PRNewswire/ ... leader in dairy research, today announced a new collaboration ... reduce the chances that the global milk supply is ... dairy project, Cornell University has become the newest academic ... Supply Chain, a food safety initiative that includes IBM ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
Breaking Biology News(10 mins):